Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17596207 | 1.00 | MAP4K4 (0.37) | MAP4K4MEN1KMT2AGPR119SETD7 | |
| SCHEMBL17596598 | 0.80 | P2RX7 (0.33) | — | |
| SCHEMBL26094122 | 0.78 | MAP4K4 (0.37) | MAP4K4MEN1KMT2AGPR119SETD7 | |
| SCHEMBL34469080 | 0.76 | GPR119 (0.38) | MAP4K4MEN1KMT2AGPR119SETD7 | |
| SCHEMBL4400866 | 0.74 | NR1H2 (0.43) | NR1H2ALDH1A1 | |
| SCHEMBL21253287 | 0.74 | P2RX7 (0.36) | MAP4K4GPR119SETD7 | |
| SCHEMBL20099681 | 0.74 | P2RX7 (0.36) | MAP4K4GPR119SETD7 | |
| SCHEMBL4927895 | 0.73 | SETD7 (0.42) | MAP4K4GPR119SETD7HSD11B1NR1H2 | |
| SCHEMBL344752 | 0.73 | TSHR (0.56) | MAP4K4GPR119SETD7NR1H2 | |
| SCHEMBL271429 | 0.73 | TSHR (0.56) | MAP4K4GPR119SETD7NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3191488-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016039983-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118749-A1 | P2X7 MODULATORS | P2RX7, P2RX3, P2RX1 | MAP4K4 1148/4885MEN1 3055/4885KMT2A 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.